Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s (NYSE:DHR) recovery remains more uneven. Which stock looks better positioned for the next phase of the life sciences rebound?
Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. Danaher Corporation’s (NYSE:DHR) second-quarter results, on the other hand, were marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth.
Bull Case
Thermo Fisher Scientific Inc.’s (NYSE:TMO) quarter suggests that the recovery in life sciences spending is becoming increasingly broad-based. Management highlighted improving customer activity across pharmaceutical and biotechnology markets, while multiple operating segments returned to healthy growth. That is encouraging because recoveries driven by several business lines tend to be more durable than those supported by a single segment.
Thermo Fisher Scientific Inc.’s (NYSE:TMO) Life Sciences Solutions segment reinforced the recovery narrative. Reported revenue climbed 13% year over year, while organic revenue rose 3%, led by continued strength in the high-margin bioproduction business. Healthy demand in this segment is particularly encouraging because it reflects ongoing investments and supports management’s view that end-market conditions continue to improve.
Perhaps the biggest positive from the quarter was the recovery in Analytical Instruments, a business that had faced weak demand for nearly two years as biotechnology funding slowed. Its return to growth provides another indication that laboratory spending is beginning to normalize. While one quarter does not establish a trend, sustained improvement in this segment would strengthen the case that the industry’s post-pandemic downturn is easing.
Thermo Fisher Scientific Inc. (NYSE:TMO) also continued investing in product innovation through launches such as the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers. Continued innovation has historically helped the company defend its competitive position in premium analytical instruments, which could become increasingly important as customer spending gradually improves.
Danaher Corporation’s (NYSE:DHR) results also pointed to improving fundamentals, although the recovery appears less mature than Thermo Fisher’s (NYSE:TMO). The company’s Life Sciences business delivered its strongest performance in several years, while bioprocessing orders increased at a mid-teens rate despite reported revenue being affected by customer project timing. Strong orders matter because they often precede future revenue recognition, suggesting underlying customer demand may be healthier than current reported sales imply.
Management also disclosed that just over $100 million of revenue shifted into next year because of customer project timing. If those projects proceed as expected, that revenue has been deferred rather than lost, potentially providing an additional tailwind in future quarters. Danaher Corporation (NYSE:DHR) further noted that academic and government markets have largely stabilized. Although it stopped short of describing those markets as fully recovered, stabilization removes one of the major headwinds that weighed on life sciences spending over the past two years.
Bear Case
Despite the encouraging results, investors should avoid assuming that the recovery will mirror the extraordinary growth experienced during the pandemic. Thermo Fisher’s (NYSE:TMO) organic revenue increased 5%, representing meaningful progress but still remaining below the double-digit growth rates the company previously achieved. As a result, expectations for a rapid return to historic growth may prove optimistic. The recent recovery also remains closely tied to improving pharmaceutical and biotech spending. If funding conditions weaken again or customers scale back capital expenditures, demand for analytical instruments could soften, slowing the company’s broader recovery.
The latest earnings have also raised expectations considerably. Following management’s guidance increase, investors now expect Thermo Fisher Scientific (NYSE:TMO) to continue expanding margins while delivering stronger organic growth. With the shares already trading at a premium valuation, future upside may increasingly depend on execution rather than simply improving industry conditions.
Danaher Corporation (NYSE:DHR) still faces several challenges despite improving demand trends. Management lowered the upper end of its full-year core revenue growth outlook, reflecting continued weakness in respiratory testing and a more measured recovery across certain businesses. While those headwinds appear manageable, they suggest Danaher Corporation’s (NYSE:DHR) turnaround is progressing more gradually than Thermo Fisher’s (NYSE:TMO), leaving investors with less near-term earnings visibility.
What Does Hedge Fund Sentiment Say?
Institutional positioning also appears to favor Thermo Fisher Scientific Inc. (NYSE:TMO). Hedge fund sentiment has improved modestly for the stock: according to Insider Monkey’s database of 1,022 hedge funds, ownership increased from 113 funds in the fourth quarter of 2025 to 115 funds in the first quarter of 2026, indicating that institutional investors continue to maintain confidence in the company’s long-term outlook.
Danaher Corporation (NYSE:DHR) moved in the opposite direction. Hedge fund ownership declined from 125 funds to 110 funds over the same period, while the aggregate value of those positions also fell. Although hedge fund activity should never be viewed in isolation, the divergence suggests institutional investors currently have greater conviction in Thermo Fisher’s (NYSE:TMO) recovery story.
Overall, both companies appear positioned to benefit from a gradual recovery in life sciences spending. Thermo Fisher’s (NYSE:TMO) recovery is broader across business segments, management has demonstrated sufficient confidence to raise guidance, and institutional sentiment remains relatively stable. Danaher Corporation (NYSE:DHR) is also showing encouraging signs, particularly through improving order trends, but investors may need clearer evidence that those orders translate into sustained revenue growth before assigning the company the same premium as Thermo Fisher Scientific Inc. (NYSE:TMO).
While we acknowledge the risk and potential of TMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center